Dissociation of vasospasm-related morbidity and outcomes in patients with aneurysmal subarachnoid hemorrhage treated with clazosentan: a meta-analysis of randomized controlled trials.

Abstract

OBJECT:

Clazosentan therapy after aneurysmal subarachnoid hemorrhage (SAH) has been found to be effective in reducing the incidence of vasospasm in randomized controlled trials. However, while vasospasm-related morbidity, including delayed ischemic neurological deficits (DINDs) and delayed cerebral infarctions, was consistently decreased, statistical significance was not demonstrated and outcomes were not affected by clazosentan treatment. The objective of this meta-analysis was to determine whether clazosentan treatment after aneurysmal SAH significantly reduced the incidence of DINDs and delayed cerebral infarctions and improved outcomes.

METHODS:

All randomized controlled trials investigating the effect of clazosentan were retrieved via searches with sensitive and specific terms. Six variables were abstracted after the assessment of the methodological quality of the trials. Analyses were performed following the method guidelines of the Cochrane Back Review Group.

RESULTS:

Four randomized, placebo-controlled trials met eligibility criteria, enrolling a total of 2181 patients. The meta-analysis demonstrated a significant decrease in the incidence of DINDs (relative risk [RR] 0.76 [95% CI 0.62-0.92]) and delayed cerebral infarction (RR 0.79 [95% CI 0.63-1.00]) in patients treated with clazosentan after aneurysmal SAH. However, this treatment regimen was not shown to outcomes including functional outcomes measured by Glasgow Outcome Scale-Extended (RR 1.12 [95% CI 0.96-1.30]) or mortality (RR 1.02 [95%CI 0.70-1.49]). Adverse events, including pulmonary complications, anemia, and hypotension, were all significantly increased in patients who received clazosentan therapy.

CONCLUSIONS:

The results of the present meta-analysis show that treatment with clazosentan after aneurysmal SAH significantly reduced the incidence of the vasospasm-related DINDs and delayed cerebral infarctions, but did not improve poor neurological outcomes in patients with aneurysmal SAH. Further study is required to elucidate the dissociation between vasospasm-related morbidity and outcomes.

• Authors: Jian Shen, Jian-Wei Pan, Zuo-Xu Fan, Xiao-Xing Xiong, Ren-Ya Zhan
• Journal: Journal of neurosurgery (J Neurosurg) Vol. 119 Issue 1 Pg. 180-9 (Jul 2013) ISSN: 1933-0693 [Electronic] United States
• PMID: 23641823 (Publication Type: Journal Article, Meta-Analysis, Review)

Chemical References

• Dioxanes
• Endothelin A Receptor Antagonists
• Pyridines
• Pyrimidines
• Sulfonamides
• Tetrazoles
• clazosentan

Topics

• Dioxanes (therapeutic use)
• Endothelin A Receptor Antagonists
• Humans
• Morbidity
• Pyridines (therapeutic use)
• Pyrimidines (therapeutic use)
• Randomized Controlled Trials as Topic
• Subarachnoid Hemorrhage (drug therapy, mortality)
• Sulfonamides (therapeutic use)
• Tetrazoles (therapeutic use)
• Treatment Outcome
• Vasospasm, Intracranial (drug therapy, mortality, prevention & control)